The vast majority of neurons within the striatum are GABAergic medium spiny neurons (MSNs), which receive glutamatergic input from the cortex and thalamus, and form two major efferent pathways: the direct pathway, expressing dopamine D 1 receptor (D 1 R-MSNs), and the indirect pathway, expressing dopamine D 2 receptor (D 2 R-MSNs). While molecular mechanisms of MSN degeneration have been identified in animal models of striatal damage, the molecular factors that dictate a selective vulnerability of D 1 R-MSNs or D 2 R-MSNs remain unknown. Here, we combined genetic, chemogenetic, and pharmacological strategies with behavioral and neurochemical analyses, and show that the pool of cannabinoid CB 1 receptor (CB 1 R) located on corticostriatal terminals efficiently safeguards D 1 R-MSNs, but not D 2 R-MSNs, from different insults. This cell-specific response relies on the regulation of glutamatergic signaling, and is independent from the CB 1 R-dependent control of astroglial activity in the striatum. These findings define cortical CB 1 R as a pivotal synaptic player in dictating a differential vulnerability of D 1 RMSNs versus D 2 R-MSNs, and increase our understanding of the role of coordinated cannabinergic-glutamatergic signaling in establishing corticostriatal circuits and its dysregulation in neurodegenerative diseases.
Introduction
The striatum is a key node for many vital neurobiological processes such as motor activity, cognitive functions, and affective processes. A very large fraction (ca. 95%) of neurons within the striatum are GABAergic medium spiny neurons (MSNs), which receive glutamatergic inputs from the cortex and thalamus. MSNs differ in their neurochemical composition and form 2 major efferent pathways: the direct (striatonigral) pathway and the indirect (striatopallidal) pathway (Kreitzer 2009 ). MSNs in the direct pathway (herein referred to as D 1 R-MSNs) express markers such as dopamine D 1 receptor (D 1 R) and substance P, and project mainly to the substantia nigra pars reticulata and the internal segment of the globus pallidus, while MSNs in the indirect pathway (herein referred to as D 2 R-MSNs) express markers such as dopamine D 2 receptor (D 2 R) and enkephalin, and project mainly to the external segment of the globus pallidus, which, in turn, projects to the subthalamic nucleus. A large number of molecular and cellular mechanisms that lead to the degeneration of MSNs has been defined in preclinical models of striatal damage (Mitchell and Griffiths 2003; Han et al. 2010; Rikani et al. 2014 ). However, a key unanswered question for understanding the pathobiology of MSNs is what precise molecular and cellular factors can dictate a selective susceptibility of D 1 R-MSNs or D 2 R-MSNs to neurotoxic stimuli. Although the basic electrophysiological properties of D 1 R-MSNs and D 2 R-MSNs are rather similar, in general D 2 R-MSNs (1) are intrinsically more excitable, (2) have fewer primary dendrites and thus a smaller dendritic surface area, and (3) display a higher frequency of spontaneous excitatory postsynaptic currents and a unique pattern of large-amplitude excitatory events, all of which supports the notion that D 2 R-MSNs may be cell-autonomously more susceptible than D 1 R-MSNs to damaging excitatory inputs (Kreitzer 2009; Raymond et al. 2011 ). Huntington's disease (HD), the archetypical neurodegenerative disease that originates primarily from the damage of MSNs, is characterized by differential alterations in the two MSN populations that occur at different stages of disease progression. Thus, based on studies conducted on both mouse models of HD and postmortem brain samples from HD patients, the classical view defines that D 2 R-MSNs are affected at earlier stages of the disease and to a greater extent than D 1 R-MSNs, which is consistent with the notion that early-onset chorea-like movements result from a preferential dysfunction/loss of D 2 R-MSNs, while later-onset bradykinesia and dystonia are a consequence of an additional dysfunction/loss of D 1 R-MSNs (Walker 2007; Han et al. 2010; Ross et al. 2014) .
However, there is also some evidence for the occurrence of early alterations in D 1 R-MSNs in both patients (Hedreen and Folstein 1995) and mouse models of HD ). Accordingly, D 1 R activation enhances NMDAR-evoked excitotoxic signaling on MSNs, while D 2 R activation usually reduces NMDAR-dependent responses (Chen et al. 2013; Sepers and Raymond 2014) . For example, D 1 R engagement has been shown to potentiate glutamate-mediated excitotoxic signaling to provoke the death of MSNs (Cepeda and Levine 1998; McLaughlin et al. 1998; Zeron et al. 2002; Tang et al. 2007; Paoletti et al. 2008; Chen et al. 2013) , while cocaine (Go et al. 2010 ) and methamphetamine (Jayanthi et al. 2002) administration, by overstimulating D 1 R-mediated signaling, damage MSNs at least in part by converging with glutamatergic overactivation. This evidence suggests exclusive protective mechanisms on D 1 R-MSNs that would spare them-compared with D 2 R-MSNs-in HD. Here, we tested the hypothesis that the cannabinoid CB 1 receptor (CB 1 R) drives such a differential protection of D 1 R-MSNs versus D 2 R-MSNs. CB 1 R, the main target of endocannabinoids and the cannabis active ingredient Δ9-tetrahydrocannabinol, is one of the most abundant metabotropic receptors in the basal ganglia, where it mediates inhibition of presynaptic activity (Glass et al. 2000; Katona and Freund 2008; Atwood et al. 2014) . In particular, CB 1 R (1) is expressed on both MSNs and corticostriatal projections (Katona and Freund 2008) , (2) plays a key role in the striatal control of motor behavior (Kreitzer 2009; Castillo et al. 2012) , and (3) protects MSNs in animal models of excitotoxicity (Fernandez-Ruiz et al. 2011) and HD (Blazquez et al. 2011; Mievis et al. 2011; Chiarlone et al. 2014) . By combining a wide array of genetic, chemogenetic and pharmacological strategies with behavioral and neurochemical analyses, we show that CB 1 R located on corticostriatal projections, by blunting glutamatergic output, selectively safeguards D 1 R-MSNs of the mouse dorsal striatum.
Materials and Methods

Animals
We used conditional mutant mice, generated by the CreloxP technology, in which the CB 1 R gene is primarily absent from cortical glutamatergic neurons of the dorsal telencephalon (CB 1 R floxed/floxed;Nex-Cre/+ mice; herein referred to as Glu-CB 1 R −/− mice) (Monory et al. 2006) or from astroglial cells (CB 1 R floxed/floxed;GFAP-CreERT2/+ mice; herein referred to as glial fibrillary acidic protein (GFAP)-CB 1 R −/− mice; treated with tamoxifen to induce Cre expression as described) (Han et al. 2012) . We also used BAC transgenic mice expressing the tdTomato and EGFP reporter genes under the control of the D 1 R and D 2 R promoter, respectively (Drd1a-tdTomato/Drd2-EGFP mice; colony founders kindly provided by Dr. Rosario Moratalla, Cajal Institute, Madrid, Spain) (Suarez et al. 2014) . Hemizygous mice transgenic for exon 1 of the human huntingtin gene with a largely expanded CAG tract (~250 CAG repeats; R6/2 L mice) were generated from R6/2 mice (The Jackson Laboratory) and subsequently crossed with CB 1 R floxed/floxed mice to obtain the R6/2 L: CB 1 R floxed/floxed double-mutant line as described (Chiarlone et al. 2014) . In all experiments, mutant mice were compared with their corresponding littermates. Wild-type C57BL/6 N mice were purchased from Harlan Laboratories. Animal housing, handling and assignment to the different experimental groups were conducted as described (Blazquez et al. 2011) . Except for the experiments conducted with the R6/2 L:CB 1 R floxed/floxed line (see Fig. 4 ), all animals used were male adults (ca. 8 week-old). Adequate measures were taken to minimize pain or discomfort of the animals. Mice were sacrificed by intracardial perfusion and their brains were excised for tissue analyses. All the experimental procedures used were performed in accordance with the guidelines and with the approval of the Animal Welfare Committee of Universidad Complutense de Madrid and Comunidad de Madrid, and in accordance with the directives of the European Commission.
Viral Vectors
Constructs expressing CFP-tagged human huntingtin exon 1 harboring a pathogenic polyQ tract of 94 CAG repeats or a normal, non-pathogenic polyQ tract of 16 CAG repeats (Maynard et al. 2009 ) (kindly provided by Dr. José J. Lucas, Severo Ochoa Molecular Biology Center, Madrid, Spain); HA-tagged Cre recombinase (Monory et al. 2006) ; EGFP (Chiarlone et al. 2014) ; G q -coupled human M 3 muscarinic DREADD (hM3Dq) fused to mCherry (Alexander et al. 2009 ) (kindly provided by Dr. Brian L. Roth, University of North Carolina, Chapel Hill, NC) or mCherry were subcloned in rAAV expression vectors with a minimal CaMKIIα promoter (kindly provided by Dr. Karl Deisseroth, Stanford University, Stanford, CA, USA) by using standard molecular cloning techniques. CFP-tagged polyQ constructs were also subcloned in rAAV expression vectors with a minimal GFAP promoter. All vectors used were of an AAV1/AAV2 mixed serotype, and were generated by calcium phosphate transfection of HEK293T cells and subsequent purification (Monory et al. 2006) . Vectors were injected stereotactically either into the dorsal striatum (vectors diluted in 3 μL PBS) or into the motor cortex projecting onto the dorsal striatum (vectors diluted in 1.5 μL PBS). In the case of the striatum, each animal received one bilateral injection at coordinates (mm to bregma): antero-posterior +0.5, lateral ±2.0, dorso-ventral −3.5.
In the case of the cortex, each animal received 2 bilateral injections at coordinates (mm to bregma): antero-posterior +1.5, lateral ±1.2, dorso-ventral −1.7; and antero-posterior −0.5, lateral ±1.2, dorso-ventral −1.2. We have described previously the placement of the rAAV vectors within the cortex and the striatum under those conditions (Chiarlone et al. 2014; Blazquez et al. 2015; Bellocchio et al. 2016 
Confocal Microscopy
Coronal free-floating sections (30 μm-thick) were obtained from paraformaldehyde-perfused mouse brains. Samples were incubated with antibodies against NeuN (1:500; Chemicon #MAB377), DARPP-32 (1:1000; BD #611520), D 1 R (1:500; Frontier Science #af500), D 2 R (1:500; Frontier Science #af750), S100β
(1:500; Abcam #ab868) or GFAP-Cy3 (1:1000; Sigma #C 9205), followed by staining with the corresponding Alexa Fluor 488, 594 or 647 antibodies as appropriate (1:1000; Life Technologies). Nuclei were visualized with DAPI. Analysis of marker-protein immunoreactivity in the dorsal striatum was conducted as described (Bellocchio et al. 2016 ) in a 1-in-10 series per animal (from bregma +1.5 to −0.5 coronal coordinates). For DARPP-32, D 1 R and D 2 R, data were calculated as immunoreactive area per total cell nuclei, and expressed as percentage of the control. For NeuN, as well as for tdTomato and EGFP fluorescence in Drd1a-tdTomato/Drd2-EGFP mice, data were calculated as number of positive cells per total cell nuclei, and expressed as percentage of the control. Confocal fluorescence images were acquired using TCS-SP2 software and a SP2 AOBS microscope (Leica). Images were analyzed with ImageJ software (NIH).
Behavior
Motor coordination (RotaRod performance) was evaluated along 3 consecutive days as described (Bellocchio et al. 2016) . Ambulation analyses were conducted in an automated actimeter (ActiTrack; Panlab), as described (Bellocchio et al. 2016) , after acute (30 min) treatment with vehicle or SKF-81297 (1 mg/ kg, i.p.). Specifically, one day after termination of chronic pharmacological treatments and RotaRod assays, half of the animals within each experimental group was injected with vehicle, the other half was injected with SKF-81297, and ambulation was measured. The day after, the treatments were crossed-over and ambulation was measured again. For each animal, SKF-81297-induced ambulation over vehicle-induced ambulation (in cm) was determined.
Microdialysis
Extracellular concentrations of glutamate and GABA were measured in the dorsal striatum of 8 week-old Glu-CB 1 R −/− mice and their CB 1 R floxed/floxed littermates by brain microdialysis in vivo (Rodriguez-Navarro et al. 2009 ). The active area of the microdyalisis probe (CMA Microdyalisis AB) was implanted in the striatum at coordinates: 0.5 mm caudal to bregma, 2 mm lateral to midline, 3.5 mm below the dura. The probes were perfused with a standard or modified KRB solution (122 mM NaCl, 3 mM KCl, 0.4 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 25.2 mM NaHCO 3 , 1.2 mM CaCl 2 ) at a flow rate of 2 μL/min with a syringe minipump (Bionalytical Systems). A perfusion period of 90 min without sampling was conducted to enable the recovery of basal amino acid levels after probe implantation. Then, perfusate samples were collected every 15 min and stored at −80°C until analysis. For amino acid determinations, dialysates were derivatized with ortho-phthaldialdehyde. The fluorescent derivatized amino acids were separated by reversed-phase chromatography on a Micra C18 column (33-3-4.6 mm, particle size 1.5 mm) by gradient elution. The mobile phase consisted of solvent A (50 mM sodium acetate, pH 5.88) and solvent B (methanol) with a binary gradient. Solvent flow rate was adjusted to 0.5 mL/min, and the injection volume was 10 μL. Fluorescence detection (Perkin-Elmer LS4) was performed at 365 and 455 nm for excitation and emission wavelengths, respectively. Amino acids were identified by their retention times, and their concentrations were calculated by comparing them to calibrated amino acid external standard solutions (1.5 μM).
t-test, as appropriate. A P-value of <0.05 was considered significant. Graphs and statistics were generated by GraphPad Prism 6.0.
Results
D 1 R-MSNs and D 2 R-MSNs are Equally Vulnerable to Cell-Autonomous Mutant Huntingtin-Induced Damage
To evaluate the potentially different vulnerability of D 1 R-MSNs and D 2 R-MSNs to huntingtin-induced damage we first used a rAAV-vector delivery strategy based on the expression of CFPtagged human huntingtin exon 1 harboring a pathogenic polyQ tract of 94 CAG repeats (herein used as a model of mutant huntingtin, mtHtt) or a normal, non-pathogenic polyQ tract of 16 CAG repeats (herein used as a model of wild-type huntingtin, wtHtt). The expression of the transgene was driven by a minimal calcium/calmodulin-dependent protein kinase II-α (CaMKIIα) promoter in order to confine it to the main cell populations affected in HD, namely MSNs (when viral injections were performed into the dorsal striatum) or cortical glutamatergic neurons (when viral injections were performed into the motor cortex). Viral inoculation was conducted in BAC transgenic mice expressing the tdTomato and EGFP reporter genes under the control of the D 1 R or D 2 R promoter, respectively (Fig. 1A ). The extent of wtHtt or mtHtt transgene expression at the time points used in the study was comparable between striatum and cortex, and, within the striatum, between D 1 R-MSNs and D 2 R-MSNs (Supplementary Fig. S1A -E). Expression of mtHtt in MSNs of the dorsal striatum for 2 weeks produced a remarkable loss of the pan-neuronal marker NeuN and the pan-MSN marker dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), as well as a parallel reduction of cells that were positive for tdTomato fluorescence (i.e., D 1 R-MSNs) or EGFP fluorescence (i.e., D 2 R-MSNs) (Fig. 1B,C) . This observation was supported by conducting immunofluorescence experiments with antibodies raised against each of the two receptors (Fig. 1B,C) . Of note, D 1 R-MSNs and D 2 R-MSNs were equally vulnerable to mtHtt-induced damage (Fig. 1B,C) . Moreover, this loss of MSN markers had a notable functional impact as evidenced by the impairment of RotaRod performance, a well-established motor coordination paradigm that relies, at least largely, on striatal function (Fig. 1B) . In contrast to this damaging effect of mtHtt expressed by MSNs in situ, no significant loss of neuronal markers or decline in RotaRod performance was observed when mtHtt was selectively expressed in principal neurons of the motor cortex, either 2 weeks (data not shown) or even 4 weeks after viral injection (Fig. 1D) .
Taken together, these data indicate that D 1 R-MSNs and D 2 RMSNs are equally sensitive to cell-autonomous mtHtt-induced toxicity, and that expression of mtHtt in cortical principal neurons is not sufficient per se to produce a significant damage of MSNs.
Expression of Mutant Huntingtin in the Cortex Damages D 1 R-MSNs but not D 2 R-MSNs upon CB 1 R Pharmacological Blockade
It is not known whether CB 1 R-evoked neuroprotection may be selective for different MSN populations, and, if so, which precise population(s) of CB 1 R molecules would be involved in such effect. To evaluate this question we first injected -as aboveCaMKIIα promoter-driven wtHtt or mtHtt-expressing rAAV vectors into the dorsal striatum or motor cortex of D 1 RtdTomato/D 2 R-EGFP reporter mice, and subsequently treated the mice with vehicle or the CB 1 R-selective antagonist SR141716 (rimonabant) at 1 mg/kg/day (i.p.) for 2 weeks (viral inoculation into the striatum) or 4 weeks (vital inoculation into the cortex) ( Fig. 2A) . Rimonabant did not affect striatumautonomous mtHtt-mediated loss of D 1 R-MSN or D 2 R-MSN markers, nor worsened motor coordination deficits under these conditions (Fig. 2B) . In remarkable contrast, CB 1 R pharmacological blockade aggravated those hallmarks of striatal integrity when mtHtt was selectively expressed in principal neurons of the motor cortex (Fig. 2C) . Moreover, MSN damage under these conditions exclusively involved D 1 R-MSNs, while D 2 R-MSNs remained unaffected (Fig. 2C) .
Taken together, these observations support that, when CB 1 R activity is compromised, expression of mtHtt in cortical principal neurons determines a dissimilar susceptibility to damage of D 1 R-MSNs versus D 2 R-MSNs.
CB 1 R Located on Corticostriatal Projections Protects D 1 RMSNs but not D 2 R-MSNs from Cortex-Elicited Damage
To provide further support to the aforementioned notion we used three different experimental paradigms in which cortical CB 1 R function and neuronal activity were manipulated in vivo in a spatiotemporally-selective manner.
In a first experimental paradigm we injected conditional mutant mice bearing a genetic deletion of CB 1 R in dorsal telencephalic glutamatergic neurons (CB 1 R floxed/floxed;Nex-Cre/+ mice;
herein referred to as Glu-CB 1 R −/− mice) (Monory et al. 2006) , and CB 1 R floxed/floxed control littermates, with CaMKIIα promoterdriven wtHtt or mtHtt-expressing rAAV vectors into the motor cortex (Fig. 3A) . As above, no significant mtHtt-evoked striatal toxicity was observed in control mice (Fig. 3B,C) . In contrast, cortical mtHtt induced a neurotoxic effect on the striatum of Glu-CB 1 R −/− mice, as determined by a loss of striatal DARPP-32 expression as well as a decline in RotaRod performance (Fig. 3B) . Remarkably, and in line with the rimonabant experiment on D 1 R-tdTomato/D 2 R-EGFP reporter mice described above, the impact of cortical mtHtt expression on Glu-CB 1 R −/− mice involved D 1 R-MSNs exclusively, while D 2 R-MSNs remained intact (Fig. 3C) . In a second experimental paradigm, we crossed R6/2L mice, a transgenic model of HD that systemically expresses exon 1 of the human huntingtin gene comprising a largely expanded CAG tract, with CB 1 R floxed/floxed mice, thus generating a R6/2L: CB 1 R floxed/floxed line, that allows the spatiotemporally-controlled excision of the loxP-flanked CB 1 R gene by Cre recombinase (Chiarlone et al. 2014) . These R6/2L:CB 1 R floxed/floxed animals (and CB 1 R floxed/floxed littermates) were injected into the dorsal striatum or the motor cortex with a rAAV-vector encoding Cre (or EGFP) under the control of the CaMKIIα promoter (Fig. 4A) . We had previously shown that, under these conditions, CB 1 R gene inactivation in the motor cortex -but not the dorsal striatumof R6/2 L:CB 1 R floxed/floxed mice reduced striatal DARPP-32 expression and RotaRod performance (Chiarlone et al. 2014) . As shown in Fig. 4B , this procedure of selective CB 1 R gene inactivation in dorsal-striatum MSNs did not affect D 1 R-MSNs or D 2 RMSNs expression. In contrast, selective CB 1 R gene inactivation in cortical principal neurons impacted D 1 R-MSNs, while D 2 RMSNs were not affected (Fig. 4C) . In a third experimental paradigm, we sought to extrapolate the above observations on cortical mtHtt-induced striatal damage to another model of cortex-initiated striatal damage. Thus, we selectively enhanced neuronal activity with a designer receptor exclusively activated by designer drug (DREADD). This chemogenetic technique is based on the expression of engineered GPCRs that are selectively activated by systemically bioavailable, brain-penetrant and otherwise pharmacologically inert ligands such as clozapine-N-oxide (CNO) (Lee et al. 2014 ). Specifically, wild-type C57BL/6N mice were injected into the motor cortex with a rAAV-vector encoding a G q protein-coupled DREADD (hM3Dq) fused to mCherry (or only mCherry as control) driven by the CaMKIIα promoter. Animals were subsequently treated with vehicle or CNO in conditions known to evoke sustained cortical activation and thereby excitotoxic damage on the striatum (10 mg/kg/day, i.p. for 4 weeks; Fig. 5A ) (Alexander et al. 2009; Chiarlone et al. 2014) . In agreement with previous data (Chiarlone et al. 2014; Bellocchio et al. 2016) , the effects elicited by CNO in DREADDexpressing mice were specific and not due to an off-target action of the drug (Gomez et al. 2017) as shown by the lack of overt effects in control mCherry-expressing animals (Fig. 5B,C) . Moreover, CB 1 R pharmacological blockade (rimonabant at 1 mg/ kg/day, i.p. for 4 weeks; Fig. 5A ) sensitized mice to striatal damage upon prolonged cortical overactivation, and this effect entailed D 1 R-MSNs but not D 2 R-MSNs (Fig. 5B,C) . Taken together, these findings support that CB 1 R located on corticostriatal projections protects D 1 R-MSNs but not D 2 R-MSNs from damage initiated at cortical principal neurons.
CB 1 R Located on Corticostriatal Projections Protects D 1 R-MSNs from Cortex-Elicited Damage by Inhibiting Glutamatergic Transmission
To evaluate whether cortical CB 1 R controls glutamatergic signaling onto the striatum we first measured by in vivo microdialysis extracellular glutamate concentration in the dorsal striatum of Glu-CB 1 R −/− mice and CB 1 floxed/floxed littermates. KCl-induced neuronal depolarization enhanced glutamate levels in Glu-CB 1 R −/− mice compared to control animals ( Fig. 6A) . As a control we analyzed in parallel GABA concentration and found no significant change upon cortical CB 1 R genetic ablation (Fig. 6A) . We subsequently isolated striatal synaptosomes from Glu-CB 1 R −/− mice and CB 1 R floxed/floxed littermates, and measured glutamate release, thus assessing the action of CB 1 R located on corticostriatal terminals. In agreement with the aforementioned microdialysis experiments, KCl-evoked glutamate release from striatal synaptosomes was enhanced upon CB 1 R genetic deletion (Fig. 6B) .
To assess the functional impact of the CB 1 R receptormediated control of glutamatergic signaling on striatal integrity in vivo we injected Glu-CB 1 R −/− mice and CB 1 R floxed/floxed littermates with CaMKIIα promoter-driven wtHtt or mtHttexpressing vectors into the motor cortex, and treated them with vehicle or the NMDAR-selective antagonist MK-801 at 0.03 mg/kg/day (i.p.) for 4 weeks (Fig. 6C) . MK-801 administration rescued the loss of striatal DARPP-32 and D 1 R expression, as well as the decline in RotaRod performance, elicited by cortical mtHtt expression in Glu-CB 1 R −/− mice (Fig. 6D) . As an additional functional readout, we found that cortical mtHtt expression in Glu-CB 1 R −/− mice impaired the characteristic stimulant-like pattern on motor activity evoked by acute administration of the D 1 R-selective agonist SKF-81297 (1 mg/kg, i.p.), thus pointing to an impact on direct-pathway striatal circuitry (Fig. 6E ). Of note, this effect was also rescued by MK-801 treatment (Fig. 6E) . Taken together, these data support that CB 1 R located on corticostriatal projections protects D 1 R-MSNs from cortical mtHttevoked damage by inhibiting glutamatergic transmission.
CB 1 R Located on Corticostriatal Projections Protects D 1 R-MSNs from Astroglia-Elicited Damage by Inhibiting Glutamatergic Transmission
Astrocytes are pivotal elements in the control of brain glutamatergic signaling (Murphy-Royal et al. 2017) . In HD, mtHtt aggregates accumulate in astrocytes from patients and animal models of the disease, and preclinical evidence supports that this can contribute to drive disease progression, at least in part through alterations in glutamate homeostasis (Benraiss et al. 2016; Jiang et al. 2016; Meunier et al. 2016; Jansen et al. 2017) . Moreover, astrocytes express CB 1 R, metabolize endocannabinoids, and modulate endocannabinergic transmission (Navarrete and Araque 2010; Stella 2010; Han et al. 2012) . Hence, we studied the possible role of astroglial CB 1 R on mtHtt-evoked striatal damage. For this purpose we injected into the dorsal striatum of C57BL/6N mice rAAV vectors encoding wtHtt or mtHtt under the control of a minimal GFAP promoter, in order to confine their expression to astrocytes (Fig. 7A) . Transgene expression was evident in a large fraction of striatal astrocytes (S100β-positive cells or GFAP-positive cells). Specifically, a ca. 70% of the total wtHtt-CFP-positive cells was found to be also S100β-positive, and a ca. 45% of the total GFAP-positive area was found to be also wtHtt-CFPpositive ( Supplementary Fig. S2A-C) . Moreover, transgene expression was undetectable in MSNs (DARPP-32-positive cells) ( Supplementary Fig. S2A,B) . Under these experimental conditions, mtHtt produced, 2 weeks after viral injection, a loss of striatal NeuN, DARPP-32 and D 1 R -but not D 2 R-immunoreactivity (Fig. 7B) , as well as an impairment of motor coordination (Fig. 7C) .
To evaluate a possible neuroprotective role of astroglial CB 1 R in this setting, conditional mutant mice bearing an inducible genetic deletion of CB 1 R in astroglial cells (CB 1 R floxed/floxed; GFAP-CreERT2/+ mice; herein referred to as GFAP-CB 1 R −/− mice) (Han et al. 2012) , as well as CB 1 R floxed/floxed littermates, were injected with GFAP promoter-driven wtHtt or mtHtt-expressing vectors into the dorsal striatum (Fig. 8A) . Selective CB 1 R genetic inactivation in astroglial cells did not exacerbate the decline of striatal DARPP-32 expression and motor coordination performance (Fig. 8B) . In contrast, selective CB 1 R genetic inactivation in principal cortical neurons (Glu-CB 1 R −/− mice) sensitized MSNs to damage induced by astroglial mtHtt expression Figure 5 . Sustained chemogenetic activation of cortical projections damages D1R-MSNs but not D2R-MSNs upon CB1R pharmacological blockade. Eight week-old C57BL/6 N mice were injected stereotactically into the motor cortex with a rAAV-vector encoding hM3Dq-mCherry (or only mCherry) under the control of a CaMKIIα promoter as previously described (Chiarlone et al. 2014) . Six weeks later, animals were treated for 4 weeks with vehicle or CNO (10 mg/kg/day, i.p), alone or in combination with vehicle or SR141716 (rimonabant; 1 mg/kg/day, i.p.). RotaRod performance was evaluated along the last 3 days of treatment, and the next day these 18 week-old animals were sacrificed for histological analyses. A, Scheme of the experiment. B, DARPP-32 in the dorsal striatum and RotaRod performance (time to fall). C, D 1 R and D 2 R immunoreactivity in the dorsal striatum. Representative images are shown. Scale bar, 50 μm. Data of neuronal markers are expressed as relative values of the mCherry-vehicle group. *P < 0.05, **P < 0.01 from the corresponding vehicle-vehicle group; # P < 0.05 from the corresponding vehicle-CNO group (n = 4-6 animals per group).
Protection of Striatal Neurons by Cortical CB 1 R Ruiz-Calvo et al. | 315 (Fig. 8B) . We next tested whether cortical CB 1 R protected MSNs from astroglial mtHtt-induced damage by blunting glutamatergic signaling. For this purpose we injected wild-type C57BL/6N mice with GFAP promoter-driven wtHtt or mtHtt-expressing vectors into the dorsal striatum, and treated them with vehicle or MK-801 (0.03 mg/kg/day, i.p.) for 2 weeks (Fig. 8C) . MK-801 administration rescued the loss of striatal DARPP-32 and D 1 R expression (Fig. 8D) , the decline in RotaRod performance (Fig. 8D) , and the impairment of SKF-81297-induced hyperactivity (Fig. 8E) elicited by mtHtt expression in striatal astrocytes. Taken together, these data support that CB 1 R located on corticostriatal projections, by inhibiting glutamatergic transmission, protects D 1 R-MSNs not only from cortical mtHtt-evoked damage, as shown above, but also from astroglial mtHttevoked damage.
Discussion
A key unanswered question in most neurodegenerative diseases is what molecular factors dictate the selective vulnerability of a particular neuronal population. In the case of HD, the pattern of neurodegeneration is very typical of regional locations and neuronal types in the striatum. Thus, MSNs, especially those found in the dorsal striatum (caudate-putamen), represent the main and earliest cell population altered, whereas, for example, striatal interneurons are typically unaffected or only mildly affected at late stages of the disease (Walker 2007) . Many studies based on techniques such as PET, autoradiography, and immunomicroscopy have reported reductions in striatal D 1 R and D 2 R density in HD patients and animal models. Nonetheless, it is generally believed that D 2 R-MSNs are affected at earlier stages of the disease and to a greater extent than D 1 R-MSNs, which is consistent with the notion that earlyonset chorea-like movements result from a preferential dysfunction/loss of D 2 R-MSNs, while later-onset bradykinesia and dystonia are a consequence of an additional dysfunction/loss of D 1 R-MSNs (Walker 2007; Han et al. 2010; Ross et al. 2014) .
Here, we unveil a new key player in this intricate scenario by showing that CB 1 R located on corticostriatal projections, through the control of glutamatergic transmission, dictates a selective protection of D 1 R-MSNs from cortical mtHtt-induced damage. CB 1 R is one of the most abundant metabotropic receptors in the basal ganglia, where endocannabinoid signaling serves as a major feedback mechanism aimed at preventing excessive presynaptic activity (Glass et al. 2000; Katona and Freund 2008; Atwood et al. 2014) . In particular, CB 1 R is highly expressed on terminals of both D 1 R-MSNs and D 2 R-MSNs, where it mediates endocannabinoid-dependent inhibition of GABA release and thus inhibition of motor activity (Katona and Freund 2008; Castillo et al. 2012) . CB 1 R is also expressed on glutamatergic terminals projecting from the cortex onto the striatum, thereby blunting glutamatergic output and mediating the so-called endocannabinoid-dependent long-term depression (Gerdeman et al. 2002; Kreitzer 2009 ). This process was initially shown to require D 2 R activation and so was proposed to occur exclusively in D 2 R-MSNs (Kreitzer and Malenka 2007) . However, other findings support that, rather than being specific for D 2 R-MSNs, endocannabinoid-dependent long-term depression may exhibit a certain preference to occur at D 2 R-MSNs over D 1 R-MSNs, and is most likely evoked by different mechanisms in each MSN population (Wang et al. 2006; Bagetta et al. 2011; Mathur and Lovinger 2012; Wu et al. 2015) . On anatomical grounds, different cortical excitatory efferents onto D 1 R-MSNs and D 2 R-MSNs were initially proposed: D 1 R-MSNs would receive input preferentially from small, bilateral intratelencephalic projections, while D 2 R-MSNs would receive input preferentially from larger, ipsilateral collaterals of the pyramidal tract (Lei et al. 2004; Reiner et al. 2010) . However, this idea has been challenged by other morphological and functional studies, in which no significant differences were found regarding the cortical targeting of D 1 R-MSNs and D 2 R-MSNs (Kress et al. 2013; Silberberg and Bolam 2015) . On the other hand, D 1 R-MSNs seem to be preferentially innervated by sensory cortical and limbic structures, while the motor cortex could preferentially target D 2 R-MSNs (Wall et al. 2013) . In any event, excitatory synapses exhibit higher release probability and larger NMDAR currents on D 2 R-MSNs than on D 1 R-MSNs (Kreitzer and Malenka 2007) . Overall, our findings are in line with the notion that CB 1 R located on corticostriatal terminals projecting onto D 2 R-MSNs could blunt physiological glutamatergic transmission preferentially aimed at controlling D 2 R-evoked dopaminergic control of motor behavior. Concertedly, the present study supports that CB 1 R located on corticostriatal terminals projecting onto D 1 RMSNs could blunt pathological glutamatergic transmission preferentially aimed at controlling D 1 R-evoked dopaminergic neurotoxicity. As D 1 R is in excess over D 2 R in the striatum, it is plausible that the former will be more significantly activated than the latter upon dopamine spillover (Raymond et al. 2011 ). On mechanistic grounds, one could speculate that, upon intense activation of glutamatergic projections, glutamate spillover out of the synapse would evoke on targeted D 1 R-MSNs the activation of the perisynaptic machinery of endocannabinoid generation, composed of type 1 metabotropic glutamate receptors (mostly mGluR 5 ), heterotrimeric G q/11 proteins, phospholipase Cβ, and diacylglycerol lipase-α, thus triggering the production of 2-AG (Uchigashima et al. 2007; Katona and Freund 2008) , which would retrogradely engage CB 1 R located on glutamatergic terminals, inhibiting in turn excess excitatory transmission (Castillo et al. 2012 ) and buffering the neurototoxic effects of extrasynaptic NMDA receptors on D 1 R-MSNs (Tang et al. 2007; Paoletti et al. 2008; Milnerwood et al. 2009; Okamoto et al. 2009; Chen et al. 2013) .
Many studies have dealt with the expression and function of CB 1 R in HD. As a matter of fact, HD most likely constitutes the best currently available model disease to assess the pathophysiological relevance and therapeutic potential of CB 1 R in neurodegenerative diseases. This is due to at least three important reasons: (1) CB 1 R is highly expressed in the dorsal striatum at both MSNs and corticostriatal projections, and plays a key role in the control of motor behavior (the process that is most characteristically affected in HD) (Katona and Freund 2008; Kreitzer 2009; Castillo et al. 2012) . (2) We (Blazquez et al. 2011) and others (Mievis et al. 2011 ) have previously demonstrated a neuroprotective role of CB 1 R in transgenic mouse models of HD. (3) An early and remarkable down-regulation of CB 1 R expression has been documented in MSNs from HD patients and animal models (Denovan-Wright and Robertson 2000; Glass et al. 2000; McCaw et al. 2004; Horne et al. 2013) . As, in contrast, the expression and function of CB 1 R located on corticostriatal projections remains unaffected along HD progression (Chiodi et al. 2012; Chiarlone et al. 2014) , it is plausible that the maintenance of CB 1 R on corticostriatal projections constitutes an adaptive mechanism aimed at buffering concerted glutamatergic-dopaminergic excitotoxicity on D 1 R-MSNs. Nonetheless, it cannot be ruled that other G i/o protein-coupled presynaptic receptors could cooperate with CB 1 R in reducing glutamatergic transmission on D 1 R-MSNs (Atwood et al. 2014 ). Evidence obtained from HD patients and mouse models shows that patterns of communication between cortical projections and MSNs become altered from very early, even asymptomatic stages of the disease, thus indicating that a dysfunctional cortical input to the striatum determines the onset and progression of neurological signs (Thu et al. 2010; Ghiglieri et al. 2012; Unschuld et al. 2012; Estrada-Sanchez and Rebec 2013) . Likewise, it is generally accepted that MSN dysfunction and associated behavioral deficits in HD are caused by the expression of mtHtt not only in MSNs (cell-autonomous toxicity) but also in cortical pyramidal neurons (non-cell-autonomous toxicity) (Gu et al. 2005; Wang et al. 2014; Estrada-Sanchez et al. 2015) . However, it is unknown whether these regional features of mtHtt expression define a potential vulnerability of D 1 R-MSNs versus D 2 R-MSNs to damage. Here, we show that, regarding the control of MSN survival by the pool of CB 1 R molecules located on corticostriatal projections, cortical pyramidal neurons constitute a key site for mtHtt expression to dictate a selective protection of D 1 R-MSNs versus D 2 R-MSNs. On the other hand, striatal astrocytes are gaining attention as possible contributors to the onset and progression of HD. The implication of astroglial damage in the dysregulation of glutamate and ion homeostasis that occurs in HD has been the focus of recent studies (Tong et al. 2014; Jiang et al. 2016) . Our data support that the astrocyte-mediated control of D 1 R-MSN integrity does not rely on the engagement of the CB 1 R pool located on astrocytes, but on the CB 1 R pool located on corticostriatal projections, which, by reducing the release of glutamate into the synaptic cleft, would blunt excitotoxicity. The CB 1 R pool located on MSNs could also contribute to controlling the number of corticostriatal connections, but does not seem to be responsible for the motor coordination deficits occurring in mouse models of HD (Chiarlone et al. 2014; Naydenov et al. 2014) . Taken together, these findings add to the current view of how non-cell-autonomous mtHtt actions orchestrate complex alterations on D 1 R-MSNs versus D 2 RMSNs, and may help to understand the intricate pathophysiology of basal ganglia disorders. or SKF-81297 (1 mg/kg, i.p.). Data are expressed as SKF-81297-induced ambulation over that of vehicle, in cm. *P < 0.05, **P < 0.01 from the corresponding wtHttvehicle group (n = 6-8 animals per group).
